Quantcast
Home > Quotes > SAGE
SAGE

Sage Therapeutics, Inc. Common Stock (SAGE) Quote & Summary Data

$147.04
*  
2.21
1.53%
Get SAGE Alerts
*Delayed - data as of Sep. 20, 2018  -  Find a broker to begin trading SAGE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 148.45 / $ 144.24
Share Volume
291,731
50 Day Avg. Daily Volume
321,934
Previous Close
$ 144.83
52 Week High / Low
$ 195.97 / $ 59.57
Market Cap
6,861,518,084
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
291,731
50 Day Avg. Daily Volume:
321,934

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.76

Trading Range

The current last sale of $147.04 is 146.84% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 148.45 $ 195.97
 Low: $ 144.24 $ 59.57

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system, or CNS, disorders, where there are no approved therapies or existing therapies are inadequate. We have a portfolio of product candidates with a current focus on modulating two critical CNS receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. We are targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible.  ... More ...  


Risk Grade

Where does SAGE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 146.06
Open Date:
Sep. 20, 2018
Close Price:
$ 147.04
Close Date:
Sep. 20, 2018

Consensus Recommendation

Analyst Info